Exact Sciences Announces Aetna Medicare Advantage
Post# of 129
Posted On: 03/04/2015 8:27:20 AM
Exact Sciences Announces Aetna Medicare Advantage to Cover Cologuard®
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ:EXAS) today announced that Aetna, one of the country's leading health plans, will cover Cologuard under its Medicare Advantage plan, reaching 967,000 members across the country. The three year agreement will go into effect on April 1, 2015.
Cologuard is the first and only FDA approved noninvasive stool-based DNA (sDNA) screening test for colon cancer. The test will be available to Aetna's Medicare Advantage members through their physician without a co-payment or co-insurance.
"We look forward to working with Aetna to provide their members with a new option for colon cancer screening. Colon cancer is most treatable when caught early, underscoring the importance of routine screening," said Kevin Conroy, Chairman and CEO of Exact Sciences.
Cologuard offers people 50 years and older who are at average risk for colorectal cancer an easy to use screening test which they can do in the privacy of their own home. Unlike many other screening options, Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test. It is the first noninvasive screening test for colorectal cancer that analyzes both sDNA and blood biomarkers to detect cancer and precancer. Cologuard is available by prescription only.
http://investor.exactsciences.com/releasedeta...eID=899850
MADISON, Wis.--(BUSINESS WIRE)-- Exact Sciences Corp. (NASDAQ:EXAS) today announced that Aetna, one of the country's leading health plans, will cover Cologuard under its Medicare Advantage plan, reaching 967,000 members across the country. The three year agreement will go into effect on April 1, 2015.
Cologuard is the first and only FDA approved noninvasive stool-based DNA (sDNA) screening test for colon cancer. The test will be available to Aetna's Medicare Advantage members through their physician without a co-payment or co-insurance.
"We look forward to working with Aetna to provide their members with a new option for colon cancer screening. Colon cancer is most treatable when caught early, underscoring the importance of routine screening," said Kevin Conroy, Chairman and CEO of Exact Sciences.
Cologuard offers people 50 years and older who are at average risk for colorectal cancer an easy to use screening test which they can do in the privacy of their own home. Unlike many other screening options, Cologuard does not require medication, dietary restrictions or bowel preparation prior to taking the test. It is the first noninvasive screening test for colorectal cancer that analyzes both sDNA and blood biomarkers to detect cancer and precancer. Cologuard is available by prescription only.
http://investor.exactsciences.com/releasedeta...eID=899850
(0)
(0)Exact Sciences Corp. (EXAS) Stock Research Links
Scroll down for more posts ▼